Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WST-09 Photodynamic Therapy in Recurrent Localized Prostate Cancer
NCT00308919Phase 2Completed
- Sponsor
- Steba Biotech
- Start
- Apr 2004
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of padeliporfin in prostate cancer (PCa), sponsored by Steba Biotech. Primary endpoint: Lesion formation induced by WST09-mediated PDT at 1 week. Started Apr 2004; status: completed.
02
Drugs
padeliporfin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00308919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00308919.